Healthcare Investment Banking Analyst: Role, Valuation, Pay, and Interview Prep

A healthcare investment banking analyst sits in an industry coverage group advising life sciences, medical device, and healthcare services companies on mergers, acquisitions, and capital raises. In May 2025, the US Bureau of Labor Statistics reported a $124,370 median annual wage for financial and investment analysts in the securities and financial investments sector before deal bonuses, and entry-level bankers register by passing the SIE and Series 79 exams. Whether a posting reads healthcare investment banking analyst, investment banking analyst healthcare, or investment banking healthcare analyst, the job pairs financial modeling with clinical, patent, and reimbursement analysis.

Updated

What a healthcare investment banking analyst does

Investment banks split junior bankers between product groups and industry coverage groups. Product teams execute one transaction type across every sector, such as mergers and acquisitions, equity capital markets, or debt underwriting. As a healthcare coverage analyst, you cover healthcare companies exclusively, building sector valuations and pitchbooks while partnering with product teams on live deals.

Under FINRA's Series 79 Investment Banking Representative framework, covered banking work includes advising on or facilitating public offerings and private placements of debt and equity, mergers and acquisitions, tender offers, financial restructurings, asset sales, divestitures, and corporate reorganizations. In the Occupational Outlook Handbook, investment bankers connect businesses seeking operating or expansion capital with investors, estimate pre-IPO valuations, verify legal readiness for public listing, and advise executives through merger execution.

Your daily schedule depends on the subsector you cover. On a follow-on equity raise for a clinical-stage biotech, your morning starts with FDA and clinical readout checks, midday goes to updating cash runway schedules and public biotech comparables, and afternoon and evening center on positioning slides with equity capital markets colleagues. On a sell-side auction for a private-equity-backed outpatient clinic chain, you update buyer logs in the morning, scrub clinic-level EBITDA adjustments, draft the Confidential Information Memorandum, and manage data room diligence in the afternoon, then refresh buyout return models at night.

Deal exposure also varies across four types of banking platforms:

  • Global bulge-bracket banks pair M&A advisory with corporate lending, underwriting large-cap pharmaceutical acquisitions, investment-grade bonds, and biotech IPOs.
  • Independent advisory boutiques focus on large M&A, spin-offs, defense mandates, and restructurings without commercial balance-sheet lending.
  • Healthcare-dedicated boutiques cover only life sciences or provider services, giving analysts concentrated work on drug licensing, royalty deals, or hospital affiliations.
  • Middle-market banks advise founder-owned and sponsor-backed clinic chains, diagnostics firms, and device makers on buyouts, roll-ups, and growth financings.

Healthcare subsectors, operating metrics, and regulations

Banks divide healthcare coverage into specialized verticals because a pre-revenue drug developer and a hospital network share almost no cash flow drivers, regulators, or buyers.

Biopharma and life sciences desks cover branded and generic pharmaceutical makers, clinical-stage and platform biotechs, contract research organizations (CROs), and contract development and manufacturing organizations (CDMOs). Large-cap pharma M&A often starts with patent cliffs: as exclusivity nears expiration on flagship drugs and generics or biosimilars enter, pharma buyers acquire biotechs or sign upfront-plus-milestone licensing deals to refill pipelines.

Medical technology and diagnostics teams advise makers of surgical systems, implants, lab platforms, and consumables across FDA device classes. Because incremental device clearances move faster than new drug trials and installed capital equipment drives recurring consumable sales, revenue is steadier than in early biotech. Healthcare services and IT teams cover hospitals, outpatient clinics, behavioral and home health, payers, and clinical software. On private-equity-backed physician practice management (PPM) roll-ups, analysts model Friendly Professional Corporation (Friendly P.C.) and Management Services Organization (MSO) structures to comply with state corporate-practice-of-medicine bans, while checking federal Stark Law self-referral rules, Anti-Kickback Statute compliance, and FTC antitrust scrutiny on hospital mergers.

Core subsectors covered by a healthcare investment banking analyst

Core subsectors covered by a healthcare investment banking analyst
SubsectorTypical ClientsCore Operating MetricsPrimary Valuation Methods
Biopharma and Life SciencesBranded and generic pharma, biotech, CROs, CDMOsTrial pass probabilities, TAM, patent cliff schedule, cash burnRisk-adjusted NPV (rNPV), licensing precedents, EV to peak sales
MedTech and DiagnosticsSurgical equipment, implants, lab platforms, consumablesProcedure volume, installed base, recurring consumable mix, gross marginEV/Revenue, EV/EBITDA, precedent M&A multiples, standard DCF
Healthcare ServicesHospitals, outpatient clinics, PPM roll-ups, home healthPayer mix (commercial, Medicare, Medicaid, self-pay), bed count, ALOS, same-store growthEV/EBITDA, LBO return models, precedent clinic multiples
Healthcare IT and Managed CareClinical and billing software, health plans, payer servicesAnnual recurring revenue (ARR), net retention, medical loss ratio, member livesEV/ARR, EV/EBITDA, growth-adjusted trading comparables
Non-Profit Health SystemsTax-exempt regional and academic hospital networksDays cash on hand, debt service coverage, inpatient volumeMunicipal credit ratios, debt capacity models, affiliation comps

Healthcare valuation and a worked rNPV example

Standard valuation tools work cleanly for profitable device makers, CROs, CDMOs, and clinic chains. You spread trading comparables and M&A precedents on EV/EBITDA and EV/Revenue, build DCF models with perpetuity or exit-multiple terminal values, and test private equity buyout returns in an LBO model.

Those multiples fail on a pre-revenue biotechnology company with negative EBITDA, binary FDA approval risk, and a finite patent life. Instead, healthcare analysts build a risk-adjusted net present value (rNPV) model. You project cash flows through patent expiration, discount them to present value, multiply commercial inflows by the cumulative probability of technical and regulatory success (PTRS), and cut off growing terminal value after exclusivity ends.

Worked example written by our team. HelixBio and all figures below are invented case data. Suppose HelixBio commits $40 million today (Year 0) to run one final pivotal trial, with a 50% approval probability and a 10% discount rate. If approved, the drug generates $110 million of unlevered free cash flow in Year 1 and $121 million in Year 2 before its patent expires and generics reduce cash flow to $0.

  • Step 1, Year 0 trial cost: HelixBio spends $40 million today regardless of trial outcome, so the probability weight is 100% and present value is -$40 million.
  • Step 2, Year 1 inflow: Discount $110 million back 1 year at 10% ($110 million divided by 1.10 equals $100 million), then multiply by the 50% approval probability to get $50 million.
  • Step 3, Year 2 inflow: Discount $121 million back 2 years at 10% ($121 million divided by 1.21 equals $100 million), then multiply by 50% to get $50 million.
  • Step 4, Post-cliff terminal value: Set terminal value after Year 2 to $0 because generic competition removes branded pricing power.
  • Step 5, Enterprise rNPV: Sum -$40 million, $50 million, and $50 million to reach an enterprise rNPV of $60 million, then add net cash to bridge to implied equity value.

Compensation, hours, and US healthcare banking hubs

In May 2025, the US Bureau of Labor Statistics reported a $102,740 national median annual wage for financial and investment analysts, with the lowest 10% earning less than $63,720 and the highest 10% earning more than $180,860. In securities, commodity contracts, and other financial investments, which employs 24% of the occupation's 377,200 analysts, the median annual wage was $124,370. By our calculation from the BLS industry wage table, securities-sector financial and investment analysts earn $21,630 more at the median than peers across all industries.

BLS profiles note that investment banking pay combines base salary with performance bonuses tied to deal production, with mid-year junior hires typically receiving a prorated stub bonus before joining the annual bonus cycle, and schedules often exceed 40 hours per week into evenings and weekends. Employment of financial and investment analysts is projected to grow 7% from 2025 to 2035, adding 27,100 jobs to reach 404,300, with about 29,500 annual openings across financial analyst roles.

Healthcare banking desks cluster in New York for large-cap M&A and financing, San Francisco and Boston for biotech, and Chicago for healthcare services. May 2023 BLS survey data shows mean wages across those hubs:

Employment and mean wages for financial and investment analysts in banking hubs (May 2023 BLS OEWS, SOC 13-2051)

Employment and mean wages for financial and investment analysts in banking hubs (May 2023 BLS OEWS, SOC 13-2051)
Benchmark or Metropolitan AreaEmploymentHourly Mean WageAnnual Mean Wage
National All-Industry Total (SOC 13-2051)325,220$54.30$112,950
Securities, Commodity Contracts, and Other Financial Investments84,550$67.19$139,750
New York-Newark-Jersey City, NY-NJ-PA51,950$70.41$146,450
San Francisco-Oakland-Hayward, CA9,350$68.86$143,240
Boston-Cambridge-Nashua, MA-NH15,000$62.15$129,270
Chicago-Naperville-Elgin, IL-IN-WI14,540$59.14$123,000

Licensing exams: SIE, Series 79, Series 63, and Series 52

Corporate investment banking analysts register as Investment Banking Representatives by passing the Securities Industry Essentials (SIE) exam and the Series 79 exam, and firms typically add the NASAA Series 63 state law exam. Anyone aged 18 or older can sit for the SIE without firm sponsorship, and passing results remain valid for 4 years. The Series 79 requires sponsorship by a FINRA member firm, requires a passing score of 73 (versus 70 on the SIE), and splits its 75 items across 3 functions: 37 on data collection and evaluation, 20 on underwriting and securities registration, and 18 on M&A, tender offers, and restructurings.

Bankers who market offerings directly to investors on road shows also need Series 7 or Series 82 registration, while analysts underwriting non-profit hospital bonds add the MSRB Series 52 exam. By our calculation from FINRA's fee table, the core corporate analyst stack (SIE at $100, Series 79 at $395, and Series 63 at $147) totals $642, or $902 when adding Series 52 ($260). Effective January 19, 2027, FINRA cuts exam retake waiting periods to 15 days (from 30 days) after a 1st or 2nd failed attempt and 60 days (from 180 days) after a 3rd.

Qualification exams for healthcare investment banking and research analysts

Qualification exams for healthcare investment banking and research analysts
ExamRole ScopeQuestionsDurationFee
SIECorequisite (open at age 18+)751 hour and 45 minutes$100
Series 79Investment Banking Representative752 hours and 30 minutes$395
Series 63NASAA Uniform State Law601 hour and 15 minutes$147
Series 52MSRB Municipal Securities (NFP hospitals)752 hours and 30 minutes$260
Series 7General Securities (road show sales)1253 hours and 45 minutes$395
Series 82Private Offerings (private placement sales)501 hour and 30 minutes$100
Series 86 and 87Equity Research AnalystS86: 85 / S87: 50S86: 4 hours 30 minutes / S87: 1 hour 45 minutesS86: $295 / S87: $195
SEC registration, information barriers, and research walls

Under Sections 15(a)(1) and 15(b) of the Securities Exchange Act of 1934, broker-dealers effecting securities transactions, including Regulation D placement agents and M&A securities advisers, must file Form BD via FINRA's Central Registration Depository (CRD), join a self-regulatory organization, and join SIPC. Within 45 days of a completed Form BD filing, the SEC grants registration or starts denial proceedings.

Because healthcare analysts handle confidential clinical readouts and merger bids, Exchange Act Section 15(f) requires written information barriers, including department isolation, physical barriers, trading restrictions, and training, to prevent insider trading. Separately, FINRA Rule 2241 and Rule 2242 separate equity and debt research from investment banking across supervision, budgets, and compensation, barring bankers from promising favorable coverage and barring research analysts from road shows or soliciting business. Under JOBS Act Section 105(b), an equity research analyst may attend an Emerging Growth Company (EGC) IPO pitch meeting with bankers if the analyst does not solicit mandates. SEC Regulation Analyst Certification (Regulation AC) also requires research reports to carry a clear, prominent certification that views reflect the analyst's personal views and disclose any recommendation-linked pay.

Education, exit paths, and 5-step interview prep plan

Entry-level analysts typically hold a bachelor's degree in finance, business, accounting, or economics, and some employers prefer a master's degree or MBA for advancement. You do not need a biology PhD or MD for entry-level healthcare banking. Your post-analyst exit options follow the subsectors you model:

  • Healthcare private equity: Services and medtech analysts use LBO and clinic roll-up modeling experience to join healthcare buyout and growth funds.
  • Life sciences venture capital and biotech hedge funds: Biopharma analysts who build rNPV models and track clinical trials move into therapeutics VC or public biotech funds.
  • Corporate and business development: Pharma, device, and managed care companies hire coverage analysts to run internal M&A and asset licensing.
  • Health system capital strategy: Non-profit hospital analysts move into health system treasury, municipal credit, or provider corporate banking.
  • Prep Step 1, Drill core technicals: Rehearse three-statement links, EV bridges, DCFs, LBOs, and accretion/dilution out loud with investment banking interview practice.
  • Prep Step 3, Know sector rules: Review FDA trial phases and IRA drug negotiations for biopharma, plus payer mix, ALOS, Stark Law, Anti-Kickback rules, and Friendly P.C. / MSO structures for services.
  • Prep Step 4, Prepare 2 deal tear-downs: Summarize one patent-cliff biopharma deal and one clinic or medtech transaction with buyer rationale and valuation multiples.

From U.S. Bureau of Labor Statistics, Occupational Outlook Handbook: Financial Analysts, U.S. Bureau of Labor Statistics, Occupational Outlook Handbook: Securities, Commodities, and Financial Services Sales Agents, U.S. Bureau of Labor Statistics, Occupational Employment and Wages, May 2023: 13-2051 Financial and Investment Analysts, FINRA, Series 79 Investment Banking Representative Exam, FINRA, Securities Industry Essentials (SIE) Exam, FINRA, Qualification Exams Fee and Duration Schedule, FINRA, Research Analyst Rules (Rule 2241 and Rule 2242), FINRA, Research Rules Frequently Asked Questions, U.S. Securities and Exchange Commission, Guide to Broker-Dealer Registration and U.S. Securities and Exchange Commission, Regulation Analyst Certification (Regulation AC) FAQ.

1 practice question and sample answer

Say your answer out loud first, then read the sample answer.

Practice question

  1. How would you value a pre-revenue, clinical-stage biotechnology company compared to a profitable outpatient clinic chain?

    Sample answer. Example answer written by our team. The applicant is invented. I would separate the two valuations because a pre-revenue drug developer and a profitable clinic operator have different cash flow drivers and risks. For the outpatient clinic chain, standard banking valuation methods apply cleanly. I would spread trading comparables and precedent clinic M&A multiples on EV/EBITDA and build an LBO model to test private equity buyout returns. While scrubbing clinic EBITDA adjustments, I would check payer mix across commercial insurers, Medicare, Medicaid, and self-pay patients, alongside same-store volume growth and clinician retention. Those multiples fail on a clinical-stage biotech. With negative EBITDA today, binary FDA approval risk, and a finite patent life, an EBITDA multiple is meaningless and a growing perpetuity terminal value ignores generic entry. Instead, I would build a risk-adjusted net present value model. In an rNPV model, you discount cash flows through patent expiration, weight commercial cash inflows by the cumulative probability of regulatory approval while keeping committed trial costs at 100%, and set post-cliff terminal value to zero. Finally, I would cross-check that rNPV against licensing precedents and EV to peak sales.

    This answer states the core contrast in the first sentence instead of reciting textbook definitions. It pairs clinic EBITDA multiples with payer mix and biotech rNPV math with approval probabilities and patent cliffs, then closes with market cross-checks.

Practice the interview, out loud

Soreno's AI interviewer asks banking fit and technical questions, follows up on your answers and scores them.

Questions people ask

What FINRA licenses does a healthcare investment banking analyst need?

Corporate analysts pass the SIE exam ($100) and the Series 79 exam ($395) to register as Investment Banking Representatives, plus the NASAA Series 63 exam ($147) for state registration. Anyone aged 18 or older can take the SIE unsponsored, while Series 79 requires FINRA member firm sponsorship. Analysts underwriting non-profit hospital municipal bonds also pass the MSRB Series 52 exam ($260).

How much does a healthcare investment banking analyst make?

In May 2025, the BLS reported a $124,370 median annual wage for financial and investment analysts in the securities and financial investments sector, versus $102,740 across all industries. In May 2023 metro data, annual mean wages reached $146,450 in New York, $143,240 in San Francisco, and $129,270 in Boston. Banking roles add performance bonuses to base pay and regularly exceed 40 hours per week.

Do you need a biology or medical degree for healthcare investment banking?

No, the Occupational Outlook Handbook states that entry-level financial analysts and securities agents typically hold a bachelor's degree in finance or business, with some employers preferring a master's degree or MBA. Interviewers test accounting and valuation first alongside working knowledge of clinical trials, patent cliffs, and reimbursement.

How does a healthcare investment banking analyst differ from an equity research analyst?

An investment banking analyst registers with Series 79 to advise companies on M&A and financings behind Section 15(f) information barriers. An equity research analyst registers with Series 86 and 87 to publish investor reports certified under SEC Regulation AC, separated from banking supervision, budgets, and pay under FINRA Rule 2241.

Why do bankers use rNPV instead of EV/EBITDA for clinical-stage biotech?

Pre-revenue clinical-stage biotechs have negative current EBITDA, binary FDA approval risk, and finite patent lives, making current EBITDA multiples and growing perpetuity terminal values unusable. An rNPV model discounts cash flows through patent expiration, weights commercial inflows by cumulative approval probability, and drops growing terminal value after generic entry.

Keep going